Literature DB >> 31774234

SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings.

Deepak Bansal1, Alan Davidson2,3, Eddy Supriyadi4, Festus Njuguna5, Raul C Ribeiro6, Gertjan J L Kaspers7,8.   

Abstract

In low- and middle-income countries (LMICs), limited resources, suboptimal risk stratification, and disproportionate patient-to-infrastructure ratio result in low survival of patients with acute myeloid leukemia (AML). A high incidence of relapse, inherent to the biology, renders management arduous. The challenge of treating AML in LMICs is of balancing the intensity of myelosuppressive chemotherapy, which appears necessary for cure, with available supportive care, which influences treatment-related mortality. The recommendations outlined in this paper are based on published evidence and expert opinion. The principle of this adapted protocol is to tailor treatment to available resources, reduce preventable toxic death, and direct limited resources toward those children who are most likely to be cured.
© 2019 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.

Entities:  

Keywords:  acute myelogenous leukemia; acute nonlymphoblastic leukemia; chemotherapy; developing country; low and middle income; protocol; treatment

Year:  2019        PMID: 31774234     DOI: 10.1002/pbc.28087

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing.

Authors:  Jeremy Wang; Nickhill Bhakta; Vanessa Ayer Miller; Mahler Revsine; Mark R Litzow; Elisabeth Paietta; Yuri Fedoriw; Kathryn G Roberts; Zhaohui Gu; Charles G Mullighan; Corbin D Jones; Thomas B Alexander
Journal:  JCO Precis Oncol       Date:  2022-04

2.  Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study.

Authors:  Yixin Hu; Aili Chen; Li Gao; Hailong He; Shuting Jiang; Xinchang Zheng; Peifang Xiao; Jun Lu; Yi Wang; Jie Li; Jianqin Li; Junjie Fan; Yanhua Yao; Jing Ling; Liyan Fan; Shengqin Cheng; Cheng Cheng; Fang Fang; Jian Pan; Qian-Fei Wang; Raul C Ribeiro; Shaoyan Hu
Journal:  Blood Adv       Date:  2021-04-13

3.  Evaluation of reporting quality in clinical practice guidelines for acute myeloid leukemia using the RIGHT checklist.

Authors:  Ding Li; Cheng Cheng; Ziming Wang; Yi Zhang; Dongbei Li; Wenping Song; Baoxia He; Xuan Wu; Wenzhou Zhang
Journal:  Ann Transl Med       Date:  2021-09

4.  Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial.

Authors:  Venkatraman Radhakrishnan; Sameer Bakhshi; Smita Kayal; Cherian Thampy; Ankit Batra; Praveen Kumar Shenoy; Hemanth Kumar; Swaminathan Rajaraman; Shilpi Chaudhary; Reema Bisht; Biswajit Dubashi; Trivadi S Ganesan
Journal:  Blood Cancer J       Date:  2022-09-06       Impact factor: 9.812

5.  Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya.

Authors:  Romy E van Weelderen; Festus Njuguna; Kim Klein; Saskia Mostert; Sandra Langat; Terry A Vik; Gilbert Olbara; Martha Kipng'etich; Gertjan J L Kaspers
Journal:  Cancer Rep (Hoboken)       Date:  2021-11-22

6.  Clinical and organizational risk factors for mortality during deterioration events among pediatric oncology patients in Latin America: A multicenter prospective cohort.

Authors:  Asya Agulnik; Adolfo Cárdenas; Angela K Carrillo; Purva Bulsara; Marcela Garza; Yvania Alfonso Carreras; Manuel Alvarado; Patricia Calderón; Rosdali Díaz; Claudia de León; Claudia Del Real; Tania Huitz; Angélica Martínez; Scheybi Miralda; Erika Montalvo; Octavia Negrín; Alejandra Osuna; Clara Krystal Perez Fermin; Estuardo Pineda; Dora Soberanis; Maria Susana Juárez Tobias; Zhaohua Lu; Carlos Rodriguez-Galindo
Journal:  Cancer       Date:  2021-02-01       Impact factor: 6.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.